Shares of Bind Therapeutics Inc. (NASDAQ:BIND) have received a consensus recommendation of “Hold” from the six analysts that are covering the firm. Five analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $6.00.
Several research analysts have recently commented on the company. Zacks Investment Research downgraded Bind Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, July 11th. Stifel Nicolaus reiterated a “hold” rating on shares of Bind Therapeutics in a report on Wednesday, July 6th.
An institutional investor recently bought a new position in Bind Therapeutics stock. Jacobs Levy Equity Management Inc. purchased a new position in shares of Bind Therapeutics Inc. (NASDAQ:BIND) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 89,900 shares of the company’s stock, valued at approximately $198,000. Jacobs Levy Equity Management Inc. owned about 0.43% of Bind Therapeutics as of its most recent filing with the SEC.
Bind Therapeutics (NASDAQ:BIND) opened at 0.78 on Friday. The firm has a 50-day moving average price of $0.52 and a 200 day moving average price of $1.17. Bind Therapeutics has a one year low of $0.35 and a one year high of $5.24.
Bind Therapeutics Company Profile
BIND Therapeutics, Inc is a biotechnology company. The Company is engaged in developing targeted therapeutics, primarily for the treatment of cancer. The Company’s product candidates are based on polymeric nanoparticles called ACCURINS, which are engineered to target specific cells and tissues in the body at sites of disease.
Receive News & Ratings for Bind Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bind Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.